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Background
Drug toxicities are limiting factors for the lifelong therapy
of HIV infection. The CCR5 receptor antagonist maraviroc
showed no long-term toxicities so far. Thus switching
from a virologically successful but not well tolerated regi-
men to maraviroc might be an future option. However,
testing of viral tropism is mandatory before the use; tests
require a plasma viral load >500 c/ml. In the majority of
patients (pts) in larger clinical centers, plasma was frozen
before starting antiretroviral therapies. These samples
would be available to define viral tropism if it can be
excluded that viral tropism changes during virological suc-
cessful therapy.
Methods
Blood samples were obtained at a mean of 7.4 days (0–
19) before starting initial ART from seven male pts, with a
mean pre-treatment viral load of 36.433 copies/ml (range
1,500–133,500), and a mean CD4 count of 509/μl (356–
650). PBMC and plasma were cryopreserved at -80°C. Pts
received 3TC, d4T, SQV and NFV in standard dosing for
mean of 92 weeks (range 72–180). A predefined STI was
performed and samples were collected at a mean of 34
days (28–59) after cessation of ART at a mean viral load of
43,967 c/ml (860–145,000). HIV co-receptor tropism was
determined in PBMC and plasma phenotypically using
the TrofileTM assay [1]. For comparison a genotypic test
was accomplished by amplifying and sequencing the V3
loop of the HIV envelope gene in pre- and post-treatment
samples. For sequence analysis and prediction of HIV co-
receptor usage the gen2pheno [co-receptor] software was
used [2].
Summary of results
In PBMC the genotypic test detected R5 viruses before and
after treatment in 7/7 pts with no change of tropism dur-
ing suppressive therapy. Genotypic results from plasma
revealed R5 viruses in 4/4 pre-treatment samples and in
all 7/7 post-treatment samples. R5 using viruses were
detected in 3/4 pre-treatment samples and 7/7 post-treat-
ment samples by using the standard phenotypic assay.
However, in one patient a duotropic D/M population was
detected phenotypically in pre-treatment samples with a
shift to R5 usage after ART, whereas genotyping failed to
detect the duotropic population in this patient.
Conclusion
The genotypic test in PBMC and plasma showed no
changes of tropism during virological successful therapy
in our patients. No shift from R5 to X4 usage was detected
during suppressive therapy by standard phenotype testing
which remains the gold standard at the moment. Thus
historical samples might be used to screen selected
aviremic patients for a switch to maraviroc.
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